PDCD11 and colorectal carcinoma: Since defective DDR limits the chemotherapy efficacy and targeting DDR pathways is a promising therapeutic strategy in CRC [54, 55], we believe that inhibition of PDCD11 should sensitize CRC cells to DDR signals and thereby benefit the patients from chemotherapy.